Molbio Diagnostics Limited has fixed the price band for its Initial Public Offering (IPO) at ₹768 to ₹807 per equity share of face value Re 1. The ₹200-crore fresh issue along with an offer for sale (OFS) of 91.66 lakh equity shares is scheduled to open for subscription on August 10, 2026.
The anchor investor portion is scheduled to be allotted on August 7, 2026. The company's shares are proposed to be listed on both the NSE and BSE, with the tentative listing date set for August 17, 2026.
The IPO consists of:
Fresh issue: ₹200 crore
Offer for Sale (OFS): 91.66 lakh equity shares
The OFS includes stake sales by promoter entities Exxora Trading and Dr Chandrasekhar Bhaskaran Nair, along with India Business Excellence Fund and seven other existing shareholders. The OFS has been reduced from the 1.25 crore shares proposed in the draft papers filed in August 2025.
The company received SEBI approval for the IPO in December 2025.
The IPO price band has been fixed at ₹768 to ₹807 per share, and investors can bid for a minimum of 18 equity shares and in multiples of 18 shares thereafter.
The key dates for the IPO are:
IPO subscription period: August 10–12, 2026
Basis of allotment: August 13, 2026 (tentative)
Refunds and Demat credit: August 14, 2026 (tentative)
Tentative listing: August 17, 2026
The IPO reserves up to 50% of the issue for Qualified Institutional Buyers (QIBs), at least 15% for Non-Institutional Investors (NIIs), and at least 35% for Retail Individual Investors (RIIs).
Molbio Diagnostics plans to utilise the proceeds from the fresh issue to expand its manufacturing and research capabilities.
₹105.5 crore will be used to establish an R&D facility, Centre of Excellence and office infrastructure through its wholly owned subsidiary Bigtec.
₹72.2 crore will be used to purchase plant, machinery and equipment for its manufacturing units in Goa and Visakhapatnam.
The remaining funds will be used for general corporate purposes.
Before the IPO, the promoters hold a 46.65% stake in the company, while investors, including V Sciences Investments, a subsidiary of Temasek Holdings, and India Business Excellence Fund, collectively own the remaining 53.35%.
Molbio Diagnostics has fixed the IPO price band at ₹768–₹807 per share, with the public issue scheduled to begin on August 10, 2026. The company plans to use the fresh issue proceeds to strengthen its manufacturing capacity and research infrastructure while existing shareholders will partially dilute their stake through the OFS.
Read stock market news in Hindi. Head to Angel One's share market news in Hindi for comprehensive coverage.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Aug 5, 2026, 10:27 AM IST
Rakesh Deshmukh
Rakesh Deshmukh is a financial content specialist with around 3 years of experience writing impactful content across equities, mutual funds, IPOs, and personal finance. At Angel One, he decodes real-time market trends and breaking news, helping investors and traders stay updated. He also helps investors make informed decisions by simplifying market fundamentals and technical analysis. He holds a bachelor’s degree in commerce.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
